

Baqsimi® Nasal Powder Featured in the September 2026 Issue of Nikkei DI

Special feature: 「点鼻レスキュー薬、集結。」

Nikkei



Drug

Global Regulatory Partners GK (GRP Japan) is pleased to share that **Baqsimi® Nasal Powder**, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of *Nikkei Drug Information* (*Nikkei DI*).

Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.

The September issue includes a special feature titled 「点鼻レスキュー薬、集結。」, focusing on nasal rescue medicines used in situations where rapid and practical administration is important.

The feature covers several therapeutic areas, including severe hypoglycemia, epileptic seizures and anaphylaxis, reflecting growing attention to intranasal drug delivery in emergency care.

Information
September 2026

BAQSIMI® AND SEVERE HYPOGLYCEMIA

Within the section on severe hypoglycemia, Nikkei DI introduces Baqsimi® Nasal Powder (glucagon) as a nasal glucagon treatment and presents practical information on its administration in an emergency.

The article includes photographs illustrating the single-use nasal device and the administration procedure, helping provide healthcare professionals with a practical overview of how the product is used.

For GRP Japan, the inclusion of Baqsimi® in this professional feature provides an opportunity for healthcare professionals to learn more about severe hypoglycemia and its management.

Publication	Nikkei Drug Information (Nikkei DI)
Issue	September 2026
Special Feature	「点鼻レスキュー薬、集結。」
Featured GRP Product	Baqsimi® Nasal Powder

Marketing Authorization Holder in Japan: Global Regulatory Partners GK

Source: Source: Nikkei Drug Information, September 2026 issue. Cover image reproduced with permission of the publisher.
Baqsimi® is a registered trademark of its respective owner.